Novel Plasma Proteomics and Phosphoproteomics Platform Captures Pleiotropic Cardiometabolic Spectrum Effects of Semaglutide in Patients with T2D and Atherosclerosis: A Companion Diagnostic Pilot Study from the STOP (Semaglutide Treatment On coronary atherosclerosis Progression) Randomized Trial
Antigoni Manousopoulou, Cory H. White, Sajad A. Hamal, Raj Nihalani, Matthew Jay Budoff, Spiros D. Garbis
This study uses proteomics and phosphoproteomics to identify semaglutide's effects on plasma proteins and phosphoproteins in T2D patients with atherosclerosis.
bioRxiv · Feb 18, 2026 · PreprintPharmacology & Toxicology